New antiretroviral may help failing PI regimens.

  • 1 September 2001
    • Vol. 16  (9) , 116-7
Abstract
Researchers at the first International AIDS Society Conference presented findings that demonstrated the potency of a new type of antiretroviral medication: the non-peptidic protease inhibitor (NPPI). We present a Q&A with Martin Markowitz, MD, an investigator with the Aaron Diamond AIDS Research Center in New York City, about this new class of drug and about research he and others have been conducting on the first NPPI drug to have Phase II data.

This publication has 0 references indexed in Scilit: